Expert NetworkExpert InterviewLLY

Slingshot members are talking to an expert! The topic is:

A Second Look: Digging into the Alzheimer's Landscape with a focus on Lilly's recent TRAILBLAZER-ALZ 2 Phase 3 study compared to Biogen's Leqembi

Executed on:May 18, 2023 4:30 PM EDT
Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert
Institution: Stanford University
  • Neurologist at Stanford with a focus on behavorial neurology.
  • Currently manages over 300 patients with Alzheimer's Disease.
  • Investigator on the CLARITY AD trial (lecanemab), the EMBARK and ENVISION studies (aducanumab), and the LEADS, AHEAD3-45, and AUTONOMY trials.

Interview Goal

The call will focus on the recent data release from the TRAILBLAZER-ALZ 2 Phase 3 clinical trial on Donanemab. The call will also compare and contrast Donanemab with Remternetug and Biogen's recently approved Leqembi (lecanemab) in Alzheimer's disease.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.